Jim Cramer: I want to see if anyone at Moderna sold stock today or tomorrow
CNBC's Jim Cramer says he wants to see if Moderna executives will sell stock before he believes the data the company is releasing about the vaccine development progress. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6
CNBC’s Jim Cramer said Wednesday that he wants to see the insider stock sales activity at Moderna before deciding how confident to be about the vaccine data the drug company released on Tuesday night.
“There’s one document that I want to see. I want to see if anyone sold any stock at Moderna today or tomorrow. Because that will really determine to me whether this thing has just got to be put (with) a total asterisk. ... Memo to Moderna: You don’t have to sell. You can sit on it,” Cramer said on “Squawk on the Street.”
CEO Stephane Bancel’s sales of stock this year and a secondary offering by the company in May have faced criticism as Moderna has provided regular updates on its Covid-19 vaccine candidate, which sometimes have contained incomplete information. Cramer said that the company has been promotional and is releasing data that it does not need to.
Bancel has sold more than 500,000 shares of the stock over the past three quarters, according to InsiderScore.com. Many of these have been transactions have been as part of predetermined trading plans.
Moderna shares popped following the release of the trial data on Tuesday night. The stock price rose more than 12% to roughly $84.50 per share on Wednesday morning.
Securities filings showed that Moderna executives sold shares over the past week, before releasing the data.
Bancel sold roughly 20,000 shares on July 10, at an average price of around $64 per share. Bancel’s moves were part of a pre-determined plan for stock sales.
Chief Medical Officer Tal Zaks made similar moves, according to securities filings. Zaks exercised stock options to buy 20,000 shares of Moderna on Monday and sold all of those shares by the end of the day.
The options were exercised at roughly $20 per share, while the series of sales had weighted averages between $64 and $78 per share.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBCTV
Видео Jim Cramer: I want to see if anyone at Moderna sold stock today or tomorrow канала CNBC Television
CNBC’s Jim Cramer said Wednesday that he wants to see the insider stock sales activity at Moderna before deciding how confident to be about the vaccine data the drug company released on Tuesday night.
“There’s one document that I want to see. I want to see if anyone sold any stock at Moderna today or tomorrow. Because that will really determine to me whether this thing has just got to be put (with) a total asterisk. ... Memo to Moderna: You don’t have to sell. You can sit on it,” Cramer said on “Squawk on the Street.”
CEO Stephane Bancel’s sales of stock this year and a secondary offering by the company in May have faced criticism as Moderna has provided regular updates on its Covid-19 vaccine candidate, which sometimes have contained incomplete information. Cramer said that the company has been promotional and is releasing data that it does not need to.
Bancel has sold more than 500,000 shares of the stock over the past three quarters, according to InsiderScore.com. Many of these have been transactions have been as part of predetermined trading plans.
Moderna shares popped following the release of the trial data on Tuesday night. The stock price rose more than 12% to roughly $84.50 per share on Wednesday morning.
Securities filings showed that Moderna executives sold shares over the past week, before releasing the data.
Bancel sold roughly 20,000 shares on July 10, at an average price of around $64 per share. Bancel’s moves were part of a pre-determined plan for stock sales.
Chief Medical Officer Tal Zaks made similar moves, according to securities filings. Zaks exercised stock options to buy 20,000 shares of Moderna on Monday and sold all of those shares by the end of the day.
The options were exercised at roughly $20 per share, while the series of sales had weighted averages between $64 and $78 per share.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBCTV
Видео Jim Cramer: I want to see if anyone at Moderna sold stock today or tomorrow канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Robinhood is 'a great opportunity' and should be bought, says Jim CramerWhy Cheap Cars Are DisappearingWhat’s Next For the U.S. Economy: Robert ShillerSolar is the fastest way to get new energy online right now, says TPG's Jim CoulterPresident Donald Trump holds news conference at the White House — 7/14/2020Jim Cramer: 'JPMorgan is not the stock to own in this market'Market Coverage - Tuesday June 28 Yahoo FinanceWatch CNBC's full interview with Berkshire Hathaway CEO Warren BuffettWe'll see a different deal market in the next 3-4 years, says Bain and Company's CashmanNajarian: Options investors are betting on a continued rebound in ChinaWealthy residents fleeing cities—Monaeo CEO on tax impact🔴 Watch Day Trading Live - June 28, NYSE & NASDAQ Stocks (Live Streaming)Stocks open higher on Goldman Sachs earnings beat and positive vaccine dataStocks grinding higher despite reopening setbacks: WFC's Chris HarveyU.S. stocks appear to be in a 'bear market rally': Portfolio managerJim Cramer: We desperately need another round of federal stimulus, despite vaccine progressJim Cramer recommends trimming positions with market near highsWATCH LIVE | Jan. 6 committee holds public hearingPositive result for 1st US COVID-19 vaccine trialJim Cramer: 'We had a lot of encouraging signs today'